Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2022
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis.International journal of dermatology · 2026Pooled it
- A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.Inflammopharmacology · 2024Pooled it
- Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.JAMA dermatology · 2025Trial
- Nemolizumab is associated with improved sleep duration and fewer nocturnal awakenings in patients with prurigo nodularis.JAAD international · 2026Article
- The SWITCH algorithm: An expert consensus on treat-to-target criteria for chronic prurigo.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Real-world Clinical Efficacy and Patient-reported Treatment Satisfaction of Nemolizumab Treatment in Prurigo Nodularis.Acta dermato-venereologica · 2026Article
- Wearable technologies in clinical trials for drug development: trends and emerging opportunities.Nature reviews. Drug discovery · 2026Review
- The skin as a sentinel organ for neurodegeneration: An underrecognized target for dementia prevention.Intractable & rare diseases research · 2026Review
- Novel therapeutic use of nemolizumab for refractory chronic scalp dysesthesia.JAAD case reports · 2026Article
- Host-Microbiome Interactions in Chronic Itch.Journal of clinical medicine · 2025Review
- Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment.Acta dermato-venereologica · 2025Article
- Effectiveness of Nemolizumab in Improving Dialysis-Associated Pruritus Refractory to Difelikefalin: A Case Report.Cureus · 2025Article
- Cutaneous Adverse Events Following Nemolizumab Administration: A Review.Journal of clinical medicine · 2025Review
- Article
- Interleukin-31 in Respiratory Type 2 Inflammatory Diseases: Mechanistic Insights and Therapeutic Potential.Journal of inflammation research · 2025Review
- Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.International journal of molecular sciences · 2024Review
- Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases.The Journal of allergy and clinical immunology · 2024Review
- Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles.Life (Basel, Switzerland) · 2024Review
- Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.American journal of clinical dermatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 6 countries.
Funding
Abstract
backgroundPatients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life and sleep deprivation. Prurigo nodularis patients have a high burden of disease, primarily due to the intensity of the itch. It is reasonable to expect that rapid relief of itch - and associated improvement of sleep - are highly valued clinical outcomes for patients. Nemolizumab is an IL-31A-receptor inhibitor that modulates the neuroimmune response with reported positive efficacy and safety data in a phase 2 study of PN.
objectivesTo evaluate the onset of action of nemolizumab on itch and sleep disturbances.
methodsPost hoc analysis of a phase 2 trial of nemolizumab 0.5 mg/kg SC vs. placebo in patients (n = 70) with moderate-to-severe PN (≥20 nodules) and severe pruritus (NRS ≥ 7). Time to significant reduction was assessed for peak pruritus (PP) and sleep disturbance (SD) using numerical rating scales (NRS), also assessed was scratching time during sleep.
resultsNemolizumab significantly reduced itch vs. placebo within 48 h (PP NRS -19.5% vs. -5.8%, respectively, P = 0.014). Significant difference between nemolizumab and placebo in reducing itch by ≥4 on PP NRS was achieved at Day 3 (23.5% vs. 0%, P < 0.001). A significant difference in SD NRS was reported by Day 4 (-24.0% vs. -4.3% placebo, P = 0.012). In addition, there was a separation between groups in SD responders (decrease of ≥4 points) in favour of nemolizumab by Day 2 (8.8% vs. 0%, P = 0.037). Sleep continued improving through Week 4, when there was a -56.0% reduction in SD NRS vs. -22.9% placebo (P < 0.001). Actigraphy data showed improvement in scratch/sleep duration for nemolizumab vs. placebo, respectively, by Week 1 (-32.15 vs. +28.15 min/h, P = 0.001).
conclusionNemolizumab has a rapid and robust onset of action in PN with itch reduction and improvement of sleep within 48 h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.